Evidence map›Paper›PMID 38034768›Full record

ArticleHeliyon2023

T-cell subset changes during the first year of pre-seasonal allergoid allergen-specific immunotherapy.

Manuel Reithofer, Simone Lisa Boell, Claudia Kitzmueller, Fritz Horak, Barbara Bohle, Beatrice Jahn-Schmid

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Manuel ReithoferDepartment of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.
Simone Lisa BoellDepartment of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.
Claudia KitzmuellerDepartment of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.
Fritz HorakAllergiezentrum Wien West, Vienna, Austria.
Barbara BohleDepartment of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.
Beatrice Jahn-SchmidDepartment of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.
Medical University of Vienna · ATAllergiezentrum Wien West · ATInstitute of Molecular Biotechnology · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergen-specific immunotherapy (AIT) is the only treatment for type I allergy, which achieves long-lasting effects. Repeated subcutaneous applications of allergen extracts cause a protective antibody response and an immune deviation of T cells. In AIT with allergoids, chemically modified allergen extracts are injected. During a so-called special pre-seasonal application scheme, after the initial phase of applying increased doses of allergoids is followed by natural allergen exposure as a maintenance phase. The effectiveness of allergoid vaccines has been described regarding the improvement of clinical symptoms and the development of protective humoral responses. In this longitudinal observational study, we sought to investigate changes at the T cell level in pre-seasonal AIT with allergoid. Different subsets within CD4

Identifiers

PMID38034768
PMCPMC10685201
OpenAlexW4388569194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.